MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times (FT) reported on Monday, citing three people familiar with the matter.

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in ...

MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026.

Merck submitted a non-binding offer for MoonLake earlier this year, valuing the business in excess of $3 billion, a premium to its $2.6 billion market value, but its initial approach was rejected ...